Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of Imsidolimab (ANB019) in Generalized Pustular Psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Pustular Psoriasis

Drugs mentioned

• Imsidolimab (ANB019) (imsidolimab)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Generalized Pustular Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2026-03-17